Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Petrylak, D.
350  Ergebnisse:
?
1

TROPHY-U-01, a phase II open-label study of sacituzumab gov..:

Loriot, Y. ; Petrylak, D.P. ; Rezazadeh Kalebasty, A....
Annals of Oncology.  35 (2024)  4 - p. 392-401 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Expert Perspectives on Controversies in Metastatic Castrati..:

Bryce, Alan H. ; Crawford, E. David ; Agarwal, Neeraj...
JU Open Plus.  2 (2024)  4 - p. , 2024
Link: https://doi.org/10.1097/..
 
?
3

A Plain Language Summary Exploring a New Treatment Combinat..:

Hoimes, Christopher J ; Flaig, Thomas W ; Milowsky, Matthew I...
Future Oncology.  20 (2024)  7 - p. 351-360 , 2024
Link: https://doi.org/10.2217/..
 
?
4

Avelumab First-line Maintenance for Advanced Urothelial Car..:

Sridhar, Srikala S. ; Powles, Thomas ; Climent Durán, Miguel Á....
European Urology.  85 (2024)  2 - p. 154-163 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Expert Perspectives on Controversies in Castration-Sensitiv..:

Crawford, E. David ; Bryce, Alan H. ; Hussain, Maha H....
JU Open Plus.  2 (2024)  4 - p. , 2024
Link: https://doi.org/10.1097/..
 
?
6

Efficacy of Antibody Drug Conjugates Alone and in Combinati..:

Grant, Michael J. ; Stockhammer, Paul ; Austin, Matthew R...
Bladder Cancer.  10 (2024)  1 - p. 9-23 , 2024
Link: https://doi.org/10.3233/..
 
?
7

Supplementary Table S8 from Phase I Dose-Escalation Study o..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947802.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
8

Supplementary Table S15 from Phase I Dose-Escalation Study ..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947823.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
9

Supplementary Table S4 from Phase I Dose-Escalation Study o..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947814.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
10

Supplementary Table S13 from Phase I Dose-Escalation Study ..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947829.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
11

Supplementary Figure S1 from Phase I Dose-Escalation Study ..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947850.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
12

Supplementary Table S11 from Phase I Dose-Escalation Study ..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947835.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
13

Supplementary Figure S3 from Phase I Dose-Escalation Study ..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947844.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
14

Supplementary Table S6 from Phase I Dose-Escalation Study o..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947808.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
15

Supplementary Table S5 from Phase I Dose-Escalation Study o..:

Daniel P. Petrylak ; Bernhard J. Eigl ; Saby George...
doi:10.1158/1078-0432.24947811.v1.  , 2024
Link: https://doi.org/10.1158/..
 
1-15